Paper Details

  1. Home
  2. Paper Details

Centrally Acting Agents for Obesity: Past, Present, and Future.

Author: CoulterAnn A, GreenwayFrank L, RebelloCandida J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Obesity is now recognized as a chronic disease. This review looks at how central nervous system-acting drugs are used to treat it. Current drugs like phentermine/topiramate, bupropion/naltrexone, lorcaserin, and liraglutide are discussed, along with promising future drugs like tesofensine and semaglutide.
Paper Details　
Original Abstract of the Article :
For many years, obesity was believed to be a condition of overeating that could be resolved through counseling and short-term drug treatment. Obesity was not recognized as a chronic disease until 1985 by the scientific community, and 2013 by the medical community. Pharmacotherapy for obesity has adv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/30014268

データ提供：米国国立医学図書館（NLM）

The Evolving Landscape of Obesity Pharmacotherapy

Obesity, a complex and growing global health concern, has long been a target for drug development. This review examines the history, current status, and future directions of centrally acting agents for obesity, exploring how our understanding of this condition has evolved and the potential for new therapeutic approaches.

From Amphetamines to Multi-Target Strategies

The authors trace the evolution of obesity pharmacotherapy, highlighting the challenges and successes in this field. Early attempts to treat obesity focused on amphetamines, but these drugs were ultimately withdrawn due to concerns about addiction and side effects. More recent approaches have involved targeting multiple neurotransmitter pathways, such as in the case of phentermine/topiramate, which acts on dopamine, norepinephrine, and GABA pathways. The review also discusses other current therapies, such as bupropion/naltrexone, lorcaserin, and GLP-1 receptor agonists like liraglutide.

A Promise of New Horizons in Obesity Management

The authors explore the promising developments in obesity pharmacotherapy, including new drugs like tesofensine, semaglutide, and setmelanotide. These agents target different pathways involved in appetite regulation and metabolism, offering potential for improved efficacy and safety. This review underscores the importance of ongoing research and innovation in developing more effective and safe treatments for obesity. Just as a camel adapts to survive in the harsh desert environment, researchers are constantly seeking new strategies to combat the challenges of obesity.

Dr.Camel's Conclusion

This review provides a comprehensive overview of the history, current status, and future directions of centrally acting agents for obesity. The evolution of obesity pharmacotherapy from amphetamines to multi-target strategies reflects our growing understanding of the complex interplay between brain, gut, and metabolism. With ongoing research and innovation, there is hope for developing more effective and safe treatments to address this global health challenge.

Date :
  1. Date Completed 2019-05-16
  2. Date Revised 2019-07-01
Further Info :

Pubmed ID

30014268

DOI: Digital Object Identifier

NIHMS1500064

Related Literature

Article Analysis
・Effects of phentermine and topiramate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.